title: [Simultaneous combination of adriamycin, bleomycin, cyclohexyl-chloroethyl nitrosourea with dimethyl-triazeno imidazole carboxamide in the treatment of Hodgkin's lymphoma].
abstract: Sixteen patients with Hodgkin's (10) and non-Hodgkin's (6) lymphoma were treated by the "ABCD scheme", which is a combination of adriamycin (25-30 mg/m2 day 1), bleomycin (15 mg day 1-5), CCNU (60 mg/m2 day 1) and DIC (90-100 mg/m2 day 1-5). 15 results are evaluable and included 5 complete remissions, 5 partial remissions, 2 stabilizations, 2 progressions and 1 early death (remission rate: 66%). 45 ABCD courses were given. 8 patients received more than one course (maximum 7 courses). Toxicity was tolerable and consisted mainly of myelodepression, nausea, vomiting and muco-cutaneous alterations. Two patients died following toxicity, one from myelosuppression and the other from interstitial pulmonary fibrosis. The results suggest that this combination can be useful where the usual chemotherapy combination fails.
mesh_terms: D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D003606:Dacarbazine / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013280:Stomatitis / Q000139:chemically induced; D014226:Triazenes / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D009607:Nitrosourea Compounds; D014226:Triazenes; D001761:Bleomycin; D003606:Dacarbazine; D004317:Doxorubicin
vernacular_title: Combinaison simultanée d'adriamycine, de bléomycine, de cyclohexyl-chloroéthyl-nitrosourée et de diméthyl-triazéno-imidazole-carboxamide dans le traitement des lymphomes hodgkiniens ou non